(EWTX) Edgewise Therapeutics - Overview
Stock: EDG-5506, EDG-7500, Pipeline
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 88.0% |
| Relative Tail Risk | -17.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -20.01 |
| Character TTM | |
|---|---|
| Beta | 1.110 |
| Beta Downside | 1.849 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.81% |
| CAGR/Max DD | 0.63 |
Description: EWTX Edgewise Therapeutics January 16, 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a U.S.-based biopharma focused on small-molecule therapies for genetically defined muscle disorders. Its lead candidate, EDG-5506, is an oral drug currently in Phase II trials targeting the underlying pathology of dystrophinopathies such as Duchenne and Becker muscular dystrophy. A second program, EDG-7500, is in Phase I and aims to treat hypertrophic cardiomyopathy and other severe cardiac conditions.
Beyond these two assets, Edgewise is building a precision-medicine pipeline that modulates specific muscle proteins, positioning the company to address a broader set of rare myopathies. As of the latest quarterly report (Q3 2024), the firm reported ~ $150 million in cash and marketable securities, giving it a runway into 2026 under its current burn rate of roughly $30 million per year. The company received FDA Fast Track designation for EDG-5506 in 2023, which could accelerate regulatory review if Phase II data prove compelling.
The biotechnology sector is benefiting from a 12 % CAGR in R&D spending on rare-disease therapeutics and increasing payer willingness to cover high-value orphan drugs, both of which underpin Edgewise’s commercial upside. However, the outcomes of early-stage trials remain highly uncertain, and any delay or negative result would materially affect valuation. For investors seeking a deeper, data-driven assessment, a quick look at Edgewise’s metrics on ValueRay may help surface additional risk-adjusted insights.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -157.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -1.20 > 1.0 |
| NWC/Revenue: 26.1k% < 20% (prev 21.3k%; Δ 4739 % < -1%) |
| CFO/TA -0.23 > 3% & CFO -132.2m > Net Income -157.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 26.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.5m) vs 12m ago 12.45% < -2% |
| Gross Margin: -2.93% > 18% (prev -0.72%; Δ -220.3% > 0.5%) |
| Asset Turnover: 0.39% > 50% (prev 0.44%; Δ -0.05% > 0%) |
| Interest Coverage Ratio: -9.97 > 6 (EBITDA TTM -172.5m / Interest Expense TTM -17.5m) |
Altman Z'' -15.00
| A: 0.95 (Total Current Assets 573.9m - Total Current Liabilities 21.6m) / Total Assets 583.5m |
| B: -0.85 (Retained Earnings -496.2m / Total Assets 583.5m) |
| C: -0.32 (EBIT TTM -174.8m / Avg Total Assets 547.4m) |
| D: -19.96 (Book Value of Equity -495.4m / Total Liabilities 24.8m) |
| Altman-Z'' Score: -19.67 = D |
What is the price of EWTX shares?
Over the past week, the price has changed by +3.37%, over one month by +26.85%, over three months by +70.28% and over the past year by +1.43%.
Is EWTX a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EWTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 38.2 | 31.2% |
| Analysts Target Price | 38.2 | 31.2% |
| ValueRay Target Price | 31.2 | 7.3% |
EWTX Fundamental Data Overview February 03, 2026
Revenue TTM = 2.12m USD
EBIT TTM = -174.8m USD
EBITDA TTM = -172.5m USD
Long Term Debt = 4.18m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.01m USD (from shortTermDebt, last quarter)
Debt = 4.18m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.42b USD (2.98b + Debt 4.18m - CCE 563.3m)
Interest Coverage Ratio = -9.97 (Ebit TTM -174.8m / Interest Expense TTM -17.5m)
EV/FCF = -18.25x (Enterprise Value 2.42b / FCF TTM -132.6m)
FCF Yield = -5.48% (FCF TTM -132.6m / Enterprise Value 2.42b)
FCF Margin = -6262 % (FCF TTM -132.6m / Revenue TTM 2.12m)
Net Margin = -7424 % (Net Income TTM -157.2m / Revenue TTM 2.12m)
Gross Margin = -2.93% ((Revenue TTM 2.12m - Cost of Revenue TTM 2.18m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.15 (Enterprise Value 2.42b / Total Assets 583.5m)
Interest Expense / Debt = 74.31% (Interest Expense 3.11m / Debt 4.18m)
Taxrate = 21.0% (US default 21%)
NOPAT = -138.1m (EBIT -174.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 26.51 (Total Current Assets 573.9m / Total Current Liabilities 21.6m)
Debt / Equity = 0.01 (Debt 4.18m / totalStockholderEquity, last quarter 558.6m)
Debt / EBITDA = 0.24 (negative EBITDA) (Net Debt -41.8m / EBITDA -172.5m)
Debt / FCF = 0.32 (negative FCF - burning cash) (Net Debt -41.8m / FCF TTM -132.6m)
Total Stockholder Equity = 509.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.73% (Net Income -157.2m / Total Assets 583.5m)
RoE = -30.88% (Net Income TTM -157.2m / Total Stockholder Equity 509.2m)
RoCE = -34.05% (EBIT -174.8m / Capital Employed (Equity 509.2m + L.T.Debt 4.18m))
RoIC = -27.12% (negative operating profit) (NOPAT -138.1m / Invested Capital 509.2m)
WACC = 10.00% (E(2.98b)/V(2.98b) * Re(10.01%) + (debt cost/tax rate unavailable))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 27.62%
Fair Price DCF = unknown (Cash Flow -132.6m)
EPS Correlation: 16.93 | EPS CAGR: 27.28% | SUE: 4.0 | # QB: 1
Revenue Correlation: 20.19 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.46 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.98 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=-23.5% | Growth Revenue=+0.0%